Belite Market Capitalization from 2010 to 2024
| BLTE Stock | USD 67.44 3.42 5.34% |
Check Belite Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Belite Bio's main balance sheet or income statement drivers, such as Tax Provision of 5.2 K, Net Interest Income of 51.5 K or Interest Income of 77.7 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 14.13. Belite financial statements analysis is a perfect complement when working with Belite Bio Valuation or Volatility modules.
Belite | Market Capitalization |
Latest Belite Bio's Market Capitalization Growth Pattern
Below is the plot of the Market Cap of Belite Bio ADR over the last few years. It is Belite Bio's Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Belite Bio's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 1.98 B | 10 Years Trend |
|
Market Cap |
| Timeline |
Belite Market Capitalization Regression Statistics
| Arithmetic Mean | 300,191,864 | |
| Geometric Mean | 286,987,339 | |
| Coefficient Of Variation | 37.14 | |
| Mean Deviation | 72,504,773 | |
| Median | 255,169,407 | |
| Standard Deviation | 111,483,923 | |
| Sample Variance | 12428.7T | |
| Range | 347M | |
| R-Value | 0.54 | |
| Mean Square Error | 9528.6T | |
| R-Squared | 0.29 | |
| Significance | 0.04 | |
| Slope | 13,380,365 | |
| Total Sum of Squares | 174001.3T |
Belite Market Capitalization History
About Belite Bio Financial Statements
Belite Bio stakeholders use historical fundamental indicators, such as Belite Bio's Market Capitalization, to determine how well the company is positioned to perform in the future. Although Belite Bio investors may analyze each financial statement separately, they are all interrelated. For example, changes in Belite Bio's assets and liabilities are reflected in the revenues and expenses on Belite Bio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Belite Bio ADR. Please read more on our technical analysis and fundamental analysis pages.
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd. Belite Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Belite Bio ADR is a strong investment it is important to analyze Belite Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Belite Bio's future performance. For an informed investment choice regarding Belite Stock, refer to the following important reports:Check out the analysis of Belite Bio Correlation against competitors. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Belite Bio. If investors know Belite will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Belite Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.10) | Return On Assets (0.26) | Return On Equity (0.40) |
The market value of Belite Bio ADR is measured differently than its book value, which is the value of Belite that is recorded on the company's balance sheet. Investors also form their own opinion of Belite Bio's value that differs from its market value or its book value, called intrinsic value, which is Belite Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Belite Bio's market value can be influenced by many factors that don't directly affect Belite Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Belite Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Belite Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Belite Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.